Prevalence of germline <i>BRCA1/2</i> pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10).

ABSTRACT:

Background

Assessment of germline (g) BRCA1/2 status is recommended for all patients with HER2-negative metastatic breast cancer (MBC) to identify candidates for poly(ADP-ribose) polymerase (PARP) inhibitor therapy, which is not always possible in clinical practice due to limited testing resources. In this study, we investigate the cross-sectional prevalence of gBRCA1/2 pathogenic variant (PV) carriers in unselected Korean patients with HER2-negative MBC.

Methods

Patients diagnosed with HER2-negative metastatic BC receiving palliative systemic treatment were eligible for inclusion in the study. Peripheral blood was prospectively drawn from each patient and gBRCA1/2 status was assessed by next-generation sequencing using an NGeneBio BRCAaccuTest.

Findi

SUBMITTER: Ahn HK 

PROVIDER: S-EPMC12272606 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature